These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 22990331

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [Abstract] [Full Text] [Related]

  • 5. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
    Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.
    Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ.
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [Abstract] [Full Text] [Related]

  • 15. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T, Obayashi K, Fujita Y, Araki T, Nakamura K, Nakamura T, Kurabayashi M, Yamamoto K.
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [Abstract] [Full Text] [Related]

  • 16. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K.
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM, Panchenko EP, Dobrovol'skiĭ AB, Titaeva EV, Khasanova ZB, Konovalova NV, Postnov AIu, Kirienko AI.
    Ter Arkh; 2011 Mar; 83(6):59-65. PubMed ID: 21786578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.